Liliane Massade | Targeted therapy | Innovation in Neuroscience Award

Published on by Neuroscientists

Liliane Massade | Targeted therapy | Innovation in Neuroscience Award

Dr. Liliane Massade, INSERM, France.

Dr. Liliane Massade is a visionary research leader whose work integrates molecular biology, nanotechnology, and translational medicine. From her academic roots in Lebanon to her pioneering research in France, she has achieved significant milestones, including the development of siRNA-based therapies for Charcot-Marie-Tooth disease and innovations in neurodegenerative and cancer treatments. Her career spans decades of groundbreaking discoveries, interdisciplinary collaborations, and impactful mentorship. With over 78 publications, patents, and numerous awards, Dr. Massade’s contributions are both scientifically profound and globally influential.

Profile

Orcid

🌟 Early Academic Pursuits

Dr. Liliane Massade’s academic journey began with her passion for biology and education. After earning her Master’s in Biology from Lebanese University in 1982, she followed her calling as a teacher, obtaining a Teaching Diploma from Ecole Normale, Lebanon, in 1981. Her thirst for knowledge led her to Paris Diderot University, where she completed an Advanced Studies Diploma (DEA) in Population Genetics and Evolution in 1986. By 1990, she had earned her Ph.D. in Population Genetics and Evolution, marking the start of her illustrious career. In 1996, she achieved the Authorization to Supervise Research (HDR), solidifying her role as a mentor and leader in her field.

🔬 Professional Endeavors

Dr. Massade’s career has been a symphony of innovation, leadership, and groundbreaking research. Since 2020, she has led a cutting-edge team at U1195 INSERM, Bicêtre University Hospital, focusing on targeted therapies for chemotherapy-induced peripheral neuropathies. Prior to this, she helmed teams at UMR 8203 CNRS, Gustave Roussy Institute, where she advanced anti-cancer therapies and explored molecular targets in thyroid cancer. Her earlier work at INSERM and CNRS saw her delve into estradiol signaling in breast cancer and enzymes in drug metabolism, laying the foundation for her expertise in molecular biology and translational medicine.

💡 Contributions and Research Focus

Dr. Massade’s pioneering spirit has transformed the fields of neurodegenerative diseases and oncology. She is celebrated for her groundbreaking siRNA-based therapies targeting PMP22, which have opened new horizons for Charcot-Marie-Tooth disease treatment. Her innovations extend beyond therapy, as her patented methods in nucleic acid transfer highlight her interdisciplinary approach. With a focus on integrating biology, chemistry, and nanotechnology, she leads research that merges fundamental science with clinical application, offering hope for conditions like peripheral neuropathy and neurodegeneration.

🏆 Accolades and Recognition

Throughout her career, Dr. Massade has earned prestigious accolades, including the Outstanding Achievement Award at the World Congress on Advances in Oncology in 2013 and the JW Griffin Prize for Regeneration from the Peripheral Nerve Society in 2021. Her impact is further underscored by her extensive publication record, with 78 works, an H-index of 26, and over 49 invited talks at international conferences. These honors reflect her global influence and her ability to inspire the next generation of researchers.

🌍 Impact and Influence

Dr. Massade’s contributions extend beyond her lab, as she evaluates research programs for renowned organizations like the ERC, ANR, and ARC. As a member of international committees such as LaBEX NanoSaclay, she ensures the advancement of cutting-edge nanotechnology. Her mentorship has shaped the careers of 10 postdoctoral researchers, 11 Ph.D. candidates, and 31 Master’s students, demonstrating her commitment to nurturing scientific talent.

🔗 Legacy and Future Contributions

As the co-founder of MAAsiRNA, Dr. Massade exemplifies the translation of research into real-world impact. With €7 million raised to develop therapies targeting PMP22, her work bridges the gap between science and patient care. Her vision for the future includes continued exploration of siRNA therapies and the development of innovative approaches to neuroprotection and cancer treatment. Her legacy is one of scientific excellence, interdisciplinary collaboration, and unwavering dedication to improving lives through research.

📚Publications

  • GRT-X Stimulates Dorsal Root Ganglia Axonal Growth in Culture via TSPO and Kv7.2/3 Potassium Channel Activation
    Authors: Léa El Chemali, Suzan Boutary, Song Liu, Guo-Jun Liu, Ryan J. Middleton, Richard B. Banati, Gregor Bahrenberg, Rainer Rupprecht, Michael Schumacher, Liliane Massaad-Massade
    Year: 2024

 

  • Optimizing Structure and Activity of the Squalenoyl-siRNA Nanoparticles
    Author: Liliane Massaad-Massade
    Year: 2023

 

  • Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia
    Authors: Guy Khalaf, Claudia Mattern, Mélina Begou, Odile Boespflug-Tanguy, Charbel Massaad, Liliane Massaad-Massade
    Year: 2022

 

  • The Mitochondrial Translocator Protein (TSPO): A Key Multifunctional Molecule in the Nervous System
    Authors: Léa El Chemali, Yvette Akwa, Liliane Massaad-Massade
    Year: 2022

 

  • Supramolecular Organization and Biological Interaction of Squalenoyl siRNA Nanoparticles
    Authors: Marie Caillaud, Frédéric Gobeaux, Miryana Hémadi, Suzan Boutary, Patrick Guenoun, Didier Desmaële, Patrick Couvreur, Frank Wien, Fabienne Testard, Liliane Massaad-Massade
    Year: 2021

 

  • Squalenoyl siRNA PMP22 Nanoparticles Are Effective in Treating Mouse Models of Charcot-Marie-Tooth Disease Type 1A
    Author: Liliane Massaad-Massade
    Year: 2021

 

  • Treating PMP22 Gene Duplication-Related Charcot-Marie-Tooth Disease: The Past, the Present, and the Future
    Author: Liliane Massaad-Massade
    Year: 2020

 

  • Small Interfering RNA From the Lab Discovery to Patients’ Recovery
    Authors: Marie Caillaud, Mévidette El Madani, Liliane Massaad-Massade
    Year: 2020

 

  • Newly Identified LMO3-BORCS5 Fusion Oncogene in Ewing Sarcoma at Relapse Is a Driver of Tumor Progression
    Author: Liliane Massaad-Massade
    Year: 2019

 

  • A Novel Therapeutic Approach to Colorectal Cancer in Diabetes: Role of Metformin and Rapamycin
    Author: Liliane Massaad-Massade
    Year: 2019

 

  • Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine
    Author: Liliane Massaad-Massade
    Year: 2019

 

🌟 Conclusion

Dr. Liliane Massade is a beacon of innovation and leadership in molecular biology and targeted therapies. From her academic beginnings in Lebanon to her groundbreaking contributions in France, she has forged a path of excellence that inspires scientists worldwide. With her unparalleled expertise and passion, she continues to redefine the possibilities of modern medicine, leaving an indelible mark on science and humanity.

Gan Liu | Gastrointestinal cancer| Best Researcher Award | 1358

Published on by Neuroscientists

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Mr. Gan Liu, the Affiliated Hospital of Qingdao University, China.

liu gan is a dedicated researcher and educator at qingdao university, specializing in gastric cancer diagnostics and treatment. his academic journey laid the foundation for innovative contributions to medical imaging and surgical oncology. through groundbreaking work in radiomics and robotic surgery, he has advanced diagnostic precision and surgical outcomes, significantly influencing global oncology practices. his achievements have garnered widespread recognition, marking him as a leader in his field.

 

profile

Scopus

🎓 early academic pursuits

liu gan began his academic journey with a strong foundation in medical sciences, focusing on the complexities of gastric cancer. his early education laid the groundwork for a career driven by curiosity and precision. by immersing himself in medical imaging and oncology, liu honed the skills necessary for innovative research. his dedication to learning and his commitment to advancing healthcare positioned him as a rising scholar in his field.

💼 professional endeavors

liu’s career flourished at qingdao university, where he took on pivotal roles in medical research and education. as a leading figure in oncology, he collaborated with multidisciplinary teams to develop advanced diagnostic and treatment protocols for gastric cancer. his expertise in medical imaging, particularly enhanced ct and radiomics, underscored his dedication to leveraging technology for better patient outcomes.

🔬 contributions and research focus

liu gan’s research centers on improving diagnostic precision and surgical outcomes for gastric cancer patients. he played a critical role in developing a deep learning radiomics nomogram to predict the response of metastatic lymph nodes to neoadjuvant chemotherapy. his investigations into robotic and laparoscopic total gastrectomy have provided valuable insights into optimizing surgical techniques, contributing significantly to evidence-based practice in oncology.

🏆 accolades and recognition

liu’s groundbreaking work has earned him accolades in both national and international academic circles. his contributions to gastric cancer research have been celebrated through awards, publications, and invitations to prestigious conferences. his role as a thought leader in medical imaging and oncology has cemented his reputation as a pioneer in his field.

🌍 impact and influence

liu’s work has transformed the understanding and management of gastric cancer, impacting clinical practice and patient care globally. his innovative approaches to medical imaging and surgery have set new standards in oncology. by combining technology with medical expertise, liu has influenced a new generation of researchers and clinicians, inspiring advancements in cancer treatment.

✨ legacy and future contributions

as a dedicated researcher and educator, liu gan’s legacy is one of innovation and excellence. his work continues to inspire future medical breakthroughs, with ongoing projects poised to revolutionize gastric cancer diagnostics and treatments. his vision for integrating artificial intelligence into oncology holds promise for reshaping the future of cancer care.

📚 Publications

  1. Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study
    Authors: Liu, G., Cao, S., Liu, X., Wang, K., Zhou, Y.
    Year: 2025

 

  1. Deep Learning Radiomics Nomogram Based on Enhanced CT to Predict the Response of Metastatic Lymph Nodes to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
    Authors: Zhong, H., Wang, T., Hou, M., Liu, Z., Zhou, Y.
    Year: 2024

 

  1. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis
    Authors: Zhong, H., Liu, X., Tian, Y., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: A high-volume center retrospective propensity score matching study
    Authors: Jia, Z., Cao, S., Meng, C., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial
    Authors: Liu, G., Cao, S., Liu, X., Zhong, H., Zhou, Y.
    Year: 2022

 

  1. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial
    Authors: Liu, D., Jing, X., Cao, S., Liu, G., Zhou, Y.
    Year: 2021

 

  1. Overexpression of tumour necrosis factor-α induced protein 8 is associated with prognosis in colon cancer
    Authors: Zhang, X., Li, Z., Sun, Y., Liu, X., Zhou, Y.
    Year: 2021

 

  1. Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy
    Authors: Tian, Y.-L., Cao, S.-G., Liu, X.-D., Wang, D.-S., Zhou, Y.-B.
    Year: 2020

Conclusion

liu gan’s legacy reflects a profound commitment to enhancing cancer care through research and innovation. his integration of cutting-edge technologies like artificial intelligence into clinical oncology paves the way for future breakthroughs. by inspiring the next generation of medical professionals and driving impactful healthcare solutions, liu’s work ensures lasting progress in the fight against gastric cancer.